This paper provides an overview of current and expected future use of biosimilars in Medicare Part B. As of April 2021, there were 20 Part B-covered biosimilars on the market. We expect an additional 20 biosimilars to launch through 2029, based on various industry information. We discuss how the biosimilar market share for individual products tends to grow with time and overall biosimilar market share has shown a modest upward trend in recent years. We also note how biosimilar competition puts pressure on the reference product’s cost, average sales price (ASP), and both biosimilar and reference product ASPs tend to fall over time.

This report was commissioned by the Biosimilars Forum.